Source comparison
TB-500 Before and After Real Results: Research vs Anecdotal Timelines Comparison
Dermal wounds (full-thickness) 14–21 days to 80% closure 30–40% faster re-epithelialization vs control Enhanced keratinocyte migration via actin upregulation Strongest evidence base. Diabetic wound models show consistent benefit Tendon partial tears 6–8 weeks
This comparison does not assign a generated winner or score.
- Dermal wounds (full-thickness)
- 14–21 days to 80% closure
- 30–40% faster re-epithelialization vs control
- Enhanced keratinocyte migration via actin upregulation
- Strongest evidence base. Diabetic wound models show consistent benefit
- Tendon partial tears
- 6–8 weeks to functional strength
- 20–25% improvement in tensile strength; better collagen alignment
- VEGF-mediated angiogenesis + reduced inflammation
- Promising in equine models; human data limited to case reports
- Skeletal muscle strain (Grade 2)
- 4–6 weeks to return-to-activity
- Reduced fibrosis; no significant change in myofiber regeneration rate
- Downregulation of TGF-β1 (pro-fibrotic cytokine)
- Primary benefit is scar tissue quality, not speed
- Ligament sprains
- 8–12 weeks to baseline stability
- Modest improvement in mechanical properties at 12 weeks
- Improved ECM deposition and organization
- Less robust than tendon data; mechanism overlap suggests benefit
- The timeline column reflects what published studies report. Not forum anecdotes or marketing claims. Real research shows TB-500 accelerates healing processes that operate on a weeks-to-months scale. Compounds that claim visible results in 48–72 hours are either exaggerating or addressing acute inflammation, not structural repair.